VivoSeq
Metabolic & Endocrine

Glycogen Storage Disease Type II

0

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Glycogen Storage Disease Type II is an early-stage landscape with 0 programs across 3 companies. The most active players are Sanofi, Ultragenyx, Genzyme, a Sanofi Company.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

0 programs

PreclinicalUltragenyx logo

Ultragenyx

0 programs

PreclinicalG

Genzyme, a Sanofi Company

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

4

clinical trials

Completed1 · 25%
Terminated1 · 25%
Active, not recruiting1 · 25%
Recruiting1 · 25%

Clinical Trials

Trial Activity

A Study of the Safety and Pharmacokinetics of rhGAA in Siblings With Glycogen Storage Disease Type II
Completed·Sanofi logoSanofi·Phase 2·NCT00051935·2 enrolled
Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)
Terminated·Ultragenyx logoUltragenyx·Phase 1/2·NCT04990388·9 enrolled
A Prospective Observational Study to Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)
Active, not recruiting·Sanofi logoSanofi·N/A·NCT04848779·16 enrolled
Pompe Disease Registry
Recruiting·GGenzyme, a Sanofi Company·N/A·NCT00231400·2,000 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)